ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Patient preferences and travel burden before radiotherapy for primary cutaneous lymphoma: baseline results from the S-MISR registry.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with primary cutaneous lymphoma may have substantial impairments in health-related quality of life (HRQoL) and may require referral to specialized radiation oncology centers. The current exploratory baseline analysis assessed patient preferences for quality of life (QoL) versus length of life (LoL), travel distance, and baseline HRQoL before radiotherapy.
methodsOf 130 screened patients, 82 patients with primary cutaneous lymphoma referred for radiotherapy were enrolled in the prospective S‑MISR registry between September 2019 and August 2024. Their QoL-versus-LoL preferences were assessed using the Quality-Quantity Questionnaire. Baseline HRQoL was evaluated using Skindex-29 and EORTC QLQ-C30. Travel distance to the treating radiation oncology department was analyzed overall and by lymphoma subtype.
resultsMedian age was 63 years (range 34-92), and 59 patients (72%) had advanced-stage disease. Fifty-six patients (68%) had mycosis fungoides (MF), 13 (16%) had Sézary syndrome (SS), and 13 (16%) had other primary cutaneous lymphomas. Overall, 31 patients (38%) prioritized QoL, 21 (25%) prioritized LoL, and 30 (37%) rated both equally. Median travel distance was longest for Sézary syndrome (201 km), followed by mycosis fungoides (114 km) and non-MF/SS lymphomas (65 km). Older age and longer travel distance emerged as potential factors associated with QoL preference. Baseline Skindex-29 scores indicated greater HRQoL impairment in MF and SS than in non-MF/SS lymphomas.
conclusionPatient preferences regarding QoL versus LoL vary considerably before radiotherapy. Travel burden may be an important patient-centered factor for treatment planning, shared decision-making, and future prospective radiotherapy studies.
Indexed as
Identifiers
42873235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.